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Abstract: A previous review summarized what was then known about the potential role of 
pregabalin in the treatment of patients with generalized anxiety disorder (GAD): this review 
provides an update on its pharmacological properties and presumed mechanism of action, the 
liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar 
molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but 
its mechanism of action does not appear to be mediated through effects on GABA. Instead, its 
anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the 
P/Q type voltage-gated calcium channel in “over-excited” presynaptic neurons, thereby reduc-
ing the release of excitatory neurotransmitters such as glutamate. The findings of randomized 
controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute 
treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and 
broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It 
also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. 
Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile 
of pregabalin may confer some advantages over other pharmacological treatments in the short 
term for treatment in patients with GAD.
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Clinical features and epidemiology of generalized 
anxiety disorder
Generalized anxiety disorder (GAD) is characterized by excessive and inappropriate 
worrying that is persistent (lasting more than a few months) and not restricted 
to particular circumstances. Patients have physical anxiety symptoms and key 
psychological symptoms, including restlessness, difficulty concentrating, irritability, 
muscle tension, and disturbed sleep. Patients with GAD have the same concerns 
about health, family, relationships, work, and finances as non-anxious controls but 
have a greater number of worries over minor matters. However, most patients present 
with other symptoms; many complain of poor sleep and difficulty in relaxation, but 
recurrent headaches and various aches and pains are also common. Some patients 
present repeatedly to health professionals, with pressing but long-standing physical 
symptoms that prove to be “medically unexplained”.
GAD is common in community and clinical settings. A review of the findings of 
epidemiological studies in Europe suggests a 12-month prevalence of 1.7%–3.4%,1 and 
a lifetime prevalence of around 4.3%–5.9%.2 It is probably the most common anxiety 
disorder among the elderly population.1,3 GAD is usually regarded as a chronic illness, 
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which fluctuates in severity over time. It typically emerges 
gradually4 and the onset of the full syndromal disorder is later 
than in other anxiety disorders. Outcome studies in community 
samples suggest a reasonable prognosis; for example, a 22-year 
follow up study of individuals meeting criteria for GAD found 
that less than 20% had persistent GAD.5 However, longitudinal 
studies in treatment-seeking patients generally suggest a 
prolonged and fluctuating course of illness.6
GAD is one of the more common mental disorders seen in 
primary medical care, and is associated with increased use of 
health services.7 Comorbidity with major depression or other 
anxiety disorders is exceedingly common.1 GAD and major 
depression have a similar degree of functional impairment8,9 
but patients with comorbid major depression and GAD have 
a more severe and prolonged course of illness and greater 
impairment.10 GAD is also common among patients with 
“medically unexplained” chronic pain,11 chronic physical 
ill-health,12 and excessive worrying, and GAD may worsen 
the outcome of cardiovascular disease.13
Presumed neuropsychobiology 
of generalized anxiety disorder
GAD in adult life is associated with an excess of traumatic 
experiences and undesirable life events during childhood.14 
Like other anxiety disorders, GAD is associated with 
behavioral inhibition in childhood, which is the tendency to 
be timid or shy in novel situations.15 GAD shares a common 
heritability with major depression16 and with the personality 
trait of “neuroticism”.17,18 The 5-hydroxtryptamine (5-HT; 
serotonin) transporter gene-linked polymorphic region 
short/short genotype is more frequent in patients with 
GAD,19 and variations in two sub-types of the glutamic acid 
decarboxylase gene may increase the susceptibility to anxiety 
disorders, including GAD.20,21 However, investigations of 
potential disturbances in the principal neurotransmitters 
noradrenaline (norepinephrine), 5-HT, and gamma 
aminobutyric acid (GABA) in GAD have tended to produce 
either inconsistent or unreplicated findings.
Hyperventilation is a well-known component of the 
bodily response to perceived danger, possibly because 
exhalation of carbon dioxide (CO
2
) induces a respiratory 
alkalosis which may partly compensate for a metabolic 
acidosis arising from rising levels of lactate due to increased 
physical activity. Rebreathing air enriched with 35% CO
2
 
does not induce panic attacks in patients with GAD22 nor 
does intravenous infusion of sodium lactate,23 contrary to 
the effects of these challenges in panic disorder. However, 
inhaling air enriched with 7.5% CO
2
 increases subjective 
and autonomic symptoms both in healthy volunteers and 
in patients with GAD.24 Some treatments that have been 
found efficacious in GAD (for example paroxetine and 
lorazepam) can reduce the emergence of anxiety following 
CO
2
 inhalation,25 though not all evidence is consistent.26
A series of investigations has shown that individuals 
with GAD scan the environment for cues suggesting threat;27 
develop worrying in an attempt to solve problems;28 may 
use worrying to avoid physical symptoms of anxiety;29 find 
it hard to tolerate uncertainty or ambiguity;30 and “worry 
about worrying”.31 A functional MRI study found evidence 
of increased anticipatory activity in the dorsal amygdala after 
cues indicating forthcoming aversive and neutral pictures, 
suggesting an “overall enhanced anticipatory emotional 
responsiveness in GAD” (that is, preparing for difficult 
challenges ahead).32 Investigations of the processing of 
emotional information suggest that GAD is associated with 
specific biases for mood-congruent information.33 Patients 
with GAD seem prepared to attend to threatening stimuli, 
and detect threats rapidly and effectively,34 but also tend 
to misinterpret ambiguous information as being indicative 
of threat.35 Intriguingly, these cognitive biases reduce with 
successful psychological or pharmacological treatment.36,37
Current pharmacological 
treatments for generalized 
anxiety disorder
The findings of systematic reviews38,39 and the results of 
randomized placebo-controlled trials of acute treatment of 
patients with GAD together provide substantial evidence for the 
efficacy of many antidepressant drugs, including most selective 
serotonin reuptake inhibitors (SSRI; citalopram, escitalopram, 
paroxetine, and sertraline) and the serotonin-norepinephrine 
reuptake inhibitors (SNRI; duloxetine and venlafaxine) 
and also for imipramine, trazodone, and agomelatine.40 
Other compounds with efficacy in placebo-controlled acute 
treatment studies include some benzodiazepines (alprazolam, 
diazepam, and lorazepam),41 buspirone,42 some antipsychotic 
drugs (quetiapine and trifluoperazine)43 and the antihistamine 
hydroxyzine.44 Beta-blockers are often used in primary medical 
care settings to manage physical symptoms of anxiety but 
placebo-controlled evidence of efficacy in acute treatment of 
patients with GAD is minimal.45 The findings of randomized 
placebo-controlled relapse-prevention studies in patients 
who have previously responded to acute treatment of varying 
lengths reveal a significant advantage for staying on active 
medication (including agomelatine, duloxetine, escitalopram, 
paroxetine, quetiapine, venlafaxine, and vortioxetine), when 
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compared to switching to placebo, for periods of between 
6–18 months.46
In Europe and the US, pregabalin is licensed for the 
treatment of peripheral and central neuropathic pain, and 
as an adjunctive therapy in patients with focal epileptic 
seizures with or without secondary generalization. In the US, 
pregabalin is also licensed for the treatment of fibromyalgia, 
whereas in Europe there is no license for fibromyalgia but 
it is licensed for the treatment of GAD, reflecting its proven 
efficacy in short-term and long-term treatment.
Preclinical properties and presumed 
mechanism underlying the 
anxiolytic effects of pregabalin
Since the previous review,47 there have been considerable 
advances in the understanding of the presumed mechanism 
of action of pregabalin underlying its anxiolytic effects. 
Pregabalin is a branched chain amino acid, similar in structure 
to leucine and GABA. However, it does not appear to bind 
to the GABA receptor, or to any binding site allosterically 
linked to GABA, or to the GABA transporter, or to enzymes 
involved in the synthetic or metabolic pathways of GABA.48 
It is absorbed rapidly after oral administration and achieves 
maximal plasma concentrations within 1-hour: absorption is 
dependent upon active transport with the L-type amino acid 
transporter 1 (LAT1) and is linear with proportional increases 
in plasma levels across the dose range.49
Pregabalin shows high affinity binding to the Type 1 and 
Type 2 proteins of the α
2
δ subunit of the P/Q type of voltage-
gated calcium channel. These channels consist of four protein 
subunits: the α
2
δ subunit comprises a δ protein which anchors 
the subunit to the plasma membrane, linked by a disulphide 
bond to the α
2
 protein which contains the pregabalin binding 
site. The α
2
δ subunit is a glycosylphosphatidylinositol 
(GPI)-anchored protein50 linked to a lipid raft membrane 
microdomain which appears sensitive to the physiological 
state of the cell.51
Standardized receptor-binding assays have shown that 
pregabalin has no significant binding to a wide range of 
receptor sites; conversely, a broad range of anxiolytics 





δ-2 calcium channel subunits.52 Autoradiography 
and immunostaining studies indicate that pregabalin is 
mainly bound to α
2
δ-1 subunits in the cortex, olfactory 
bulb, hypothalamus, amygdala, and hippocampus, but to 
α
2
δ-2 subunits in the cerebellum.53,54
As with other anxiolytic drugs, administration of pregabalin 
has been shown to attenuate the activation of the left anterior 
insula and left amygdala in response to emotionally charged 
visual stimuli in healthy volunteers.55 Pregabalin is also 
efficacious in the treatment of patients with GAD,56 and social 
anxiety disorder.57 These anxiolytic effects of pregabalin are 
presumed to be mediated through its actions on the α
2
δ-1 subunit, 
which leads to reductions in the availability and effects of 
excitatory neurotransmitters, including glutamate. High-affinity 
α
2
δ ligands exert potent effects in animal models of anxiety;58 
pregabalin has no anxiolytic-like effects in transgenic mice 
with specific point mutations in the voltage-gated calcium 
channel α
2
δ Type 1 protein, whereas anxiolytic-like effects are 
preserved in mice with a point mutation in the α
2
δ-2 protein.59 
A range of studies have indicated that through its effects on 
calcium channels, pregabalin administration reduces the release 
of glutamate;48 furthermore, pregabalin administration may 
reduce the synthesis of excitatory synapses60 and may block 
the trafficking of new voltage-gated calcium channels to the 
cell surface.61
Evidence base for pregabalin 
in the treatment of GAD
Our previous review noted that it was not possible to make 
definitive statements about the potential role of pregabalin in 
the overall management of patients with GAD as no placebo-
controlled trial with an SSRI as active comparator had been 
published, the effect of pregabalin on depressive symptoms 
in patients with GAD was not established, little was known 
about its longterm tolerability and patient acceptability, 
and no data was available regarding its use as a second-line 
treatment in patients who had not responded to previous 
interventions.47
The randomized double-blind placebo-controlled 
evidence base supporting the use of pregabalin in GAD 
has steadily expanded, and currently comprises six short 
term (4–6 week) fixed-dose studies;62–67 two short-term 
(8-week) flexible-dose studies, one in elderly patients,68 the 
other in younger patients;69 a single long-term (6-month) 
fixed dose relapse prevention study;70 and a short-term 
(8-week) flexible-dose study in patients who had not 
responded to previous treatment with either an SSRI or 
SNRI antidepressant (Table 1).71
Taken together, these studies demonstrate that pregabalin 
is efficacious in both acute treatment and relapse prevention. 
Its relative efficacy in acute treatment when compared 
to other medications is not firmly established, though an 
analysis of randomized controlled trials which found an 
overall mean effect size of 0.39, also found some differences 
between medication class: pregabalin, 0.50; SNRI, 0.42; 
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benzodiazepines, 0.38; SSRI, 0.36; and buspirone, 0.17.72 
The relative efficacy of pregabalin and antidepressant drugs 
in preventing relapse in patients with GAD, when compared 
to antidepressant drugs,73 is uncertain.
There have been few studies of the further management 
of patients with GAD who had not responded to first-line 
interventions. The findings of small randomized placebo-
controlled augmentation studies suggest that augmentation 
of antidepressants with antipsychotic drugs (olanzapine, 
quetiapine, and risperidone) may be beneficial,74–76 though 
the evidence for quetiapine augmentation is inconsistent77 
and uncertain for ziprasidone augmentation.78 However, 
the f indings of a recent large randomized placebo-
controlled augmentation study demonstrate that the 
addition of pregabalin to SSRI or SNRI antidepressant drugs 
is superior to continued treatment with antidepressants 
alone.71
Onset of effect and dose-response 
relationships
An early onset of effect in reducing anxiety symptoms 
is considered beneficial in treating patients with anxiety 
disorders, but the findings of randomized controlled trials 
tend to indicate that a few weeks pass before antidepressants 
are superior to placebo.40 Pregabalin has been found superior 
to placebo in reducing anxiety in patients prior to undergoing 
dental or orthopedic procedures, with an onset of effect within 
a few hours.79,80 In GAD, an assessment of the potential early 
efficacy of pregabalin has not been reported, although a 
large, placebo-controlled, flexible-dose trial which included 
Table 1 Randomized placebo-controlled trials of pregabalin in treatment of generalized anxiety disorder





arms daily dosage (n)
Efficacy?
Pande et al67 Acute treatment 
Adult patients 
HAMA $20
4 Pregabalin 150 mg (71) 
Pregabalin 600 mg (71) 






Pande et al62 Acute treatment 
Adult patients 
HAMA $20
4 Pregabalin 150 mg (69) 
Pregabalin 600 mg (70) 






Feltner et al63 Acute treatment 
Adult patients 
HAMA $20
4 Pregabalin 150 mg (70) 
Pregabalin 600 mg (66) 






Rickels et al64 Acute treatment 
Adult patients 
HAMA $20
4 Pregabalin 300 mg (91) 
Pregabalin 450 mg (90) 
Pregabalin 600 mg (89) 







Pohl et al65 Acute treatment 
Adult patients 
HAMA $20
6 Pregabalin 200 mg (78) 
Pregabalin 400 mg (89) 











6 Pregabalin 400 mg (97) 
Pregabalin 600 mg (110) 









Elderly patients (65+ years) 
HAMA $20




Kasper et al69 Acute treatment 
Adult patients 
HAMA $20
8 Pregabalin 300–600 mg (121) 





Feltner et al70 Relapse prevention 
Adult patients




Rickels et al71 Treatment resistant 
Adult patients
8 SSRi/SNRi + pregabalin 150–600 mg (180) 
SSRi/SNRi + placebo (176)
Yes 
–
Abbreviations: HAMA, Hamilton Scale for Anxiety; SSRi selective serotonin reuptake inhibitor; SNRi, serotonin-noradrenaline reuptake inhibitor.
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an assessment of efficacy at day 4 of treatment found that 
pregabalin was superior to both venlafaxine XL and placebo 
at day 4.69
For many medications, it is uncertain how long treatment 
should continue in the absence of signs of improvement, 
before concluding that a response is unlikely. However, 
the findings of post hoc analyses of data from randomized 
double-blind placebo-controlled studies with duloxetine81 
and escitalopram82 suggest that response is unlikely if there 
is no onset of clinical effect within 4 weeks of starting 
treatment. A post hoc analysis of randomized controlled 
trial data with pregabalin indicates that an onset of overall 
clinical effect within the first 2 weeks is associated with 
a 5.3-fold odds ratio of responding to treatment, whereas 
only one quarter of patients who show no onset of clinical 
effect by the second week will have responded to treatment 
at study endpoint.83
Dose-response relationships for antidepressants in 
the treatment of patients with GAD are not established, 
and for pregabalin, the evidence is mixed. Meta-analysis 
of the findings from randomized controlled trials found 
no evidence for a dose-response curve for daily dosages 
between 200–600 mg, although a 150 mg daily dosage 
was associated with a slower onset of efficacy.84 However, 
a dose-response effect was observed when comparing the 
lowest dose (150 mg/d) to the 200–600 mg dosing range. 
For the 150 mg/d dose of pregabalin, there was a somewhat 
lower short-term improvement in both the Hamilton 
Rating Scale for Anxiety (HAM-A)85 total score, and in the 
HAM-A sleep item.84 A post hoc analysis of the effects of 
pregabalin in reducing severity of psychological and physical 
anxiety symptoms indicates a 150 mg daily dosage may be 
suboptimal, whereas no dose-response effect was observed 
within a daily dosage range of between 300–600 mg.86
Effects of pregabalin in reducing 
depressive symptoms, somatic 
symptoms, and sleep disturbance
Coexisting depressive symptoms and comorbid depressive 
disorders are common in patients with a primary diagnosis 
of GAD. Many clinicians choose an antidepressant when 
treating patients with comorbid conditions, hoping that 
a single medication will prove effective in reducing both 
anxiety and depressive symptom severity. In the clinical trial 
program with pregabalin patients in which those with severe 
depressive symptoms were excluded from participation, 
but those with depressive symptoms of mild or moderate 
intensity were potentially suitable, a post hoc analysis in the 
subgroup of patients with more severe depressive symptoms 
(HAM-D $15) found that pregabalin treatment was effective 
in reducing depressive symptoms, across the dosing range 
of 150–600 mg.87 Furthermore findings from the flexible-
dose comparison of pregabalin (300–600 mg/day) and 
venlafaxine-XL (75–225 mg/day) indicate that pregabalin 
treatment was associated with a signif icantly greater 
reduction in HAM-D total score, when compared to placebo 
(P = 0.018).69
Pain and somatic symptoms, some of which can seem 
“medically unexplained”, are common complaints among 
patients with GAD, and are often the reasons leading to 
medical consultation. Pregabalin is licensed for the treatment 
of neuropathic pain and fibromyalgia, itself characterized by 
often perplexing somatic symptoms, and a post hoc analysis 
of clinical trial data has found that it is effective in reducing 
the severity of cardiovascular, respiratory, muscular, and 
gastrointestinal symptoms in GAD.86 Many patients with 
GAD are also troubled by persistent insomnia and other 
forms of sleep disturbance. In a pooled analysis of the 
clinical trial database with pregabalin, in which 54% of 
patients reported moderate-to-severe insomnia at baseline, 
treatment with pregabalin was associated with a significant 
reduction in sleep disturbance, across the dosing range of 
300–600 mg/day.88 Pregabalin was found superior to both 
placebo and venlafaxine XL in reducing sleep disturbance 
within the context of a double-blind flexible-dose study69,89 
in younger patients and treatment with pregabalin was 
associated with a significant improvement in sleep in elderly 
patients.68,89
Tolerability and safety of pregabalin
In our previous review47 we noted that the increased incidence 
of hemangiosarcoma seen in mice subject to higher exposures 
to pregabalin was thought to derive from platelet changes (and 
associated endothelial cell proliferation) that are not present 
in rats or in humans. Further analysis of genotoxicity, tumor 
incidence and tumor genetics indicates that pregabalin can act as 
a single-species (mice), single tumor-type (hemangiosarcoma) 
non-genotoxic carcinogen.90 Knowledge of the mechanism of 
hemangioma induction has increased, and it is now thought 
that increased bicarbonate, and dysregulated erythropoiesis, 
macrophage activation, and increased angiogenic growth factors 
may all be important.91 Pregabalin appears to induce hypoxia 
and endothelial cell proliferation in a species-specific manner, 
but these effects can be inhibited by vitamin E, presumably due 
to its antioxidant and antiangiogenic properties.92 Based on an 
extensive dataset, a recent review concluded that the findings 
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seen in mice are not relevant to humans at the clinical dose of 
pregabalin, and that use of pregabalin does not pose an increased 
risk for hemangiosarcoma in humans.93
The findings of randomized controlled trials indicate that 
treatment with pregabalin is generally well-tolerated, across 
the daily dosing range of 150–600 mg. In the clinical trial 
database the majority of adverse events were recorded as being 
mild-to-moderate in severity, though dizziness and somnolence 
were rated as “severe” by more than 2% of patients. A similar 
proportion of patients withdrew from further participation due 
to an adverse event (pregabalin 11.3%; placebo 9.3%).94 Most 
adverse events have an onset in the first week of treatment, and 
tend to have remitted within 3 weeks. Little is known about 
the relative tolerability of pregabalin when compared to other 
treatments; however, the adverse event profile of pregabalin 
differs to that of venlafaxine XL, pregabalin being associated 
with more prominent dizziness and vertigo, and venlafaxine 
XL with more prominent nausea,69 and a pooled analysis of 
studies that included a benzodiazepine indicates that treatment 
with pregabalin is more likely to be associated with dizziness, 
and benzodiazepine treatment more likely to be associated 
with somnolence and incoordination. The findings of a more 
recent mixed treatment comparison suggest that the tolerability 
of pregabalin in acute treatment is probably better than that of 
comparator medications.40
The potential for weight gain is a common concern among 
patients undergoing long-term treatment with antidepressant 
or anxiolytics drugs. In our earlier review47 we noted that 
weight gain of potential clinical significance (ie, more than 
7% increase) was present in 4% of patients undergoing treat-
ment with pregabalin, compared to 1.4% of those allocated 
to placebo. As a recent meta-analysis of the clinical trial 
database for pregabalin across four clinical areas (mental 
disorder, drug-resistant partial epilepsy, fibromyalgia, and 
neuropathic pain) indicates that the adverse event profile is 
similar in all four areas,95 it seems reasonable to examine 
changes in weight during pregabalin treatment for other 
conditions. In the clinical trial database of studies in post-
herpetic neuralgia or neuropathic pain, weight gain was 
reported in 3.8%–7.0% of Western patients but 11.7%–13.4% 
of  Japanese patients, perhaps due to their lower mean body 
weight;96 and in the clinical trial database for studies in 
fibromyalgia, weight gain was significantly more frequent 
with pregabalin (0.97%) than placebo (0.22%).97
Case reports have described the association of pregabalin 
treatment with the development of peripheral edema,98–101 
peripheral edema and worsened hepatic function,102 and with 
peripheral edema and pleural effusion.103 However, other 
potentially causative factors were present in all patients. The 
exact incidence of edema in patients with GAD is uncertain, 
although it was significantly more frequent with pregabalin 
(5.9%) than with placebo (1.6%) in the fibromyalgia clinical 
trial database97 and occurs in a similar proportion of patients 
with fibromyalgia or neuropathic pain.95
In our previous review,47 we noted that overdoses of 
pregabalin in approximately 100 patients had not been 
associated with unexpected adverse events or medically 
important consequences. A subsequent case report described 
the development of complete but transient atrioventricular 
block following pregabalin overdose.104 However, a review 
of 42 cases of pregabalin overdose indicates that serious 
complications are unusual,105 and a case report has described 
full recovery with general supportive care only, after 
ingestion of 8.4 grams of pregabalin, which resulted in a 
serum level of 66.5 mg/L.106
Potential for abuse of and 
dependence on pregabalin
Our earlier review47 noted that while pre-clinical studies in 
animal models had indicated that pregabalin had neither a 
benzodiazepine- or morphine-like discriminative stimulus, 
and was not self-administered in a sustained manner, some 
evidence of drug “likeability” had been seen in human 
recreational drug abusers.107 However, pregabalin does not 
appear to increase the “likeability” of opiate analgesics.108 
“Euphoria” was an adverse event in clinical trials among 
1%–10% of patients, depending on dose, compared to 0.5% 
in patients receiving placebo,94 which emphasizes the need 
for careful and continuing evaluation of any potential for 
abuse. Since entering widespread clinical use, reports of 
pregabalin abuse have appeared, often involving individuals 
with a history of abuse of other medications.109–113
Discontinuation symptoms were reported after abruptly 
stopping pregabalin within the randomized controlled 
trial program; these were more prominent after stopping 
higher daily doses,63,65 but there were significantly fewer 
withdrawal symptoms after stopping pregabalin than after 
stopping lorazepam.62 However, a number of case reports 
and case series suggest that pregabalin may be beneficial in 
facilitating withdrawal from benzodiazepines and related 
compounds.114–117 A switch study in which patients receiving 
long-term benzodiazepines were randomized to 12 weeks of 
double-blind treatment with either flexible-dose pregabalin 
or placebo while the dosage of benzodiazepines was tapered 
down, followed by a 6-week benzodiazepine-free phase, found 
that pregabalin was more beneficial (though not significantly 
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superior) than placebo in enabling patients to become 
benzodiazepine-free (51.4% versus 37%, respectively; 
P = 0.284).118 In addition, preclinical studies in animal 
models indicate that pregabalin reduces alcohol consumption 
and alcohol-seeking behavior,119 and reduces the severity 
of handling-induced seizures in mice withdrawing from 
alcohol.120 The evidence that pregabalin facilitates alcohol 
withdrawal symptoms and the maintenance of abstinence in 
detoxified patients is encouraging but inconsistent.121
Conclusion
GAD is a common, distressing, and impairing medical 
condition that tends to run a chronic or episodic course. 
A broad range of psychological and pharmacological 
interventions are available, but many patients do not respond 
to first-line approaches, and many are troubled by side effects 
that can limit treatment adherence and increase the risk of 
relapse. Pregabalin is efficacious in acute treatment and in the 
prevention of relapse, has comparable efficacy to alternative 
medications including certain benzodiazepines and the SNRI 
venlafaxine, and may have tolerability advantages over 
some comparator treatments. It is efficacious in reducing the 
severity of psychological and physical symptoms of anxiety, 
in reducing sleep disturbance, and in reducing the severity of 
coexisting depressive symptoms, and is also efficacious as a 
second-line treatment, in patients who have not responded 
to initial treatment with SSRI or SNRI antidepressants. It 
has been recommended as a potential first-line treatment in 
patients with GAD122 and in psychiatric practice is commonly 
used both as a first-line treatment and as a second-line 
treatment either on its own or as an augmentation agent.123 
Because of its beneficial effects in reducing sleep disturbance 
and somatic symptom severity, it has also been recommended 
as a first-line treatment for patients with GAD seen in 
primary care settings.124 There have been steady advances 
in understanding of its properties in animal models, and of 
the molecular and neuropsychological mechanisms thought 
to underlie its anxiolytic effects. As with all psychotropic 
medications, continuing vigilance is needed when assessing 
the potential for the development of tolerance, dependence, 
discontinuation symptoms, and abuse.
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